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Adrenomedullin (AM) is a peptide hormone with numerous
effects in the vascular systems. AM signals through theAM1 and
AM2 receptors formed by the obligate heterodimerization of aG
protein-coupled receptor, the calcitonin receptor-like receptor
(CLR), and receptor activity-modifying proteins 2 and 3
(RAMP2 and RAMP3), respectively. These different CLR-RAMP
interactions yield discrete receptor pharmacology and physio-
logical effects. The effective design of therapeutics that target
the individual AM receptors is dependent on understanding the
molecular details of the effects of RAMPs on CLR. To under-
stand the role of RAMP2 and -3 on the activation and conforma-
tion of the CLR subunit of AM receptors, we mutated 68 indi-
vidual amino acids in the juxtamembrane region of CLR, a key
region for activation of AM receptors, and determined the
effects on cAMP signaling. SixteenCLRmutations had differen-
tial effects between theAM1 andAM2 receptors. Accompanying
this, independent molecular modeling of the full-length AM-
bound AM1 and AM2 receptors predicted differences in the
binding pocket and differences in the electrostatic potential of
the two AM receptors. Druggability analysis indicated unique
features that could be used to develop selective small molecule
ligands for each receptor. The interaction of RAMP2 or RAMP3
with CLR induces conformational variation in the juxtamem-
brane region, yielding distinct binding pockets, probably via an
allosteric mechanism. These subtype-specific differences have
implications for the design of therapeutics aimed at specific AM
receptors and for understanding the mechanisms by which
accessory proteins affect G protein-coupled receptor function.
The endothelium-derived peptide hormone adrenomedullin
(AM)6 is a protective factor in the cardiovascular system and a
biomarker for cardiovascular disease (1–5). AMadministration
in human subjects has several positive outcomes, significantly
improving patient recovery from myocardial infarction, inhib-
iting myocyte apoptosis, reducing mean pulmonary arterial
pressure, and increasing cardiac output in heart failure patients
(1, 5–7). However, serious adverse hypotension in some
patients, coupled with rapid metabolism of the peptide, means
that optimal targeting of the AM system still needs to be
achieved (7, 8). The pro-angiogenic effects of AM mean that
receptor agonists or antagonists could be useful in a range of
other conditions, such as lymphedema or cancer (9). Realizing
any of these therapeutic goals, however, requires a much
greater understanding ofAMreceptor biology.Herewe explore
receptor architecture to lay the foundations for the design of
selective AM receptor ligands.
AM signals through two receptors. These both contain the
calcitonin receptor-like receptor (CLR), a class B G protein-
coupled receptor (GPCR) that has an absolute requirement for
association with a receptor activity-modifying protein (RAMP)
for ligand binding and receptor activation to occur. Association
of CLRwith RAMP2 generates the AM1 receptor, whereas CLR
with RAMP3 forms the AM2 receptor (10).
The AM1 receptor has an important role in cardiovascular
system development. Deletion of the genes for AM, CLR, or
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RAMP2 results in embryonic lethality due to the development
of hydrops fetalis and cardiovascular abnormalities (11–13).
For example,Adm/mice have small and disorganized hearts
(13). Cardiomyocyte-specific RAMP2 knock-out disrupted car-
diac metabolism and homeostasis by causing cardiac dilation
and changes inmitochondrial structure (14). Furthermore, tar-
geted RAMP2 overexpression in vascular smooth muscle sug-
gests that the AM1 receptor could protect against vascular
remodeling invoked by prolonged hypertension (15).
RAMP3knock-outmice give important insight into the likely
role of the AM2 receptor in cardiac biology. Unlike RAMP2
knock-out mice, these animals survive into old age and exhibit
normal angiogenesis (12, 16). When challenged by crossing
Ramp3/ with RenTgMKmice (a genetic model of angioten-
sin II-mediated cardiovascular disease), sex-dependent cardio-
vascular phenotypic differences emerge (i.e. renal failure and
cardiac hypertrophy occur only in male mice) (16). A separate
Ramp3/ model exhibited narrowed lymphatic vessels,
impaired lymphatic drainage, and thus post-operative lymph-
edema and prolonged inflammation (17).
Thus, the AM1 and AM2 receptors have distinct roles. In
animal models of cardiovascular disease, both the relative and
absolute expression of the AM1 and AM2 receptor subunits
change in different disease states. In the kidney of hypertensive
rats, RAMP2 expression decreases, and RAMP3 expression
increases (18). Each AM receptor is a potential drug target, and
it is important to develop selective molecules for each receptor
that can tease out the most beneficial receptor activity. For
example, AM1 receptor antagonists could be useful anti-angio-
genic agents in cancer (9). In cardiovascular disease, either
receptor could be a drug target. Receptor-selective molecules
are urgently needed to tease out the role of each receptor and
enable drug development efforts.
TheAMreceptors are compelling targets fromadrug discov-
ery perspective because of their biological effects and because
they belong to the large GPCR superfamily of transmembrane
proteins that are the cellular targets for 36% of all approved
therapeutics (19). Peptide-binding class B GPCRs (including
CLR) maintain the conserved heptahelical conformation
observed across the wider superfamily with attendant intracel-
lular loops, extracellular loops (ECLs), and a large extracellular
domain (ECD) (20). Class BGPCRpeptide ligands are known to
interact with the ECD through their C terminus, with a second
interaction of their N terminus with the juxtamembrane
domain (the ECLs and the upper region of the transmembrane
(TM) helices) that initiates receptor activation. However, the
fact that the two AM receptors share a common GPCR (CLR)
and the natural ligand (AM)makesminimal direct contact with
the RAMP ECD (21) makes the design of receptor-specific
drugs a challenge. Rational design of specific ligands would
therefore benefit from improved knowledge of the full impact
of RAMPs upon AM1 and AM2 receptor structure and func-
tion. In the pursuit of AM receptor agonists, a focus on the
regions of CLR that trigger signaling is critical.
Here we explore howRAMPs affect the CLR juxtamembrane
domain through extensive site-directed mutagenesis and
molecular modeling. Our data suggest that RAMP2 and
RAMP3 each create unique CLR conformations that may be
exploitable for the development of small molecule ligands.
Experimental Procedures
Materials—Human AM (AM(1–52)) was purchased from
American Peptide (Sunnyvale, CA). Forskolin was from Tocris
Bioscience (Wiltshire, UK). ALPHAscreen cAMP assay kits
were from PerkinElmer Life Sciences. Poly-D-lysine-coated
plates were from BD (Auckland, New Zealand). 125I-AM(13–
52) was from PerkinElmer Life Sciences.
Expression Constructs and Mutagenesis—Wild type (WT)
human CLR with an N-terminal hemagglutinin (HA) epitope
tag, human RAMP2 with an N-terminal FLAG epitope tag, and
untagged human RAMP3 were used in this study (22, 23). The
HA-CLR mutants and RAMP constructs have been described
previously (24–26).
Cell Culture and Transfection—Culture of HEK293S cells
was performed as described previously (23). Cells were counted
using a Countess CounterTM (Invitrogen) and seeded at a den-
sity of 15,000 cells/well into 96-well poly-D-lysine-coated
plates. For binding assays, 24-well plates were used (22). These
were transiently transfected using polyethyleneimine as
described previously (27).
Synthesis of Alanine-substituted AM(15–52) and Experi-
ments with Phe18 AM—For experiments investigating the role
of Phe18 in the AM peptide, we used an F18A AM(15–52) pep-
tide, alongside aWTAM(15–52) control. As is evident from the
data for full-lengthAM(1–52) andAM(15–52) (Tables 2 and 4),
these peptides have equivalent function. The AM(15–52) pep-
tides were synthesized by solid phase peptide synthesis using
the Fmoc/tert-butyl method on a 0.1-mmol scale. Briefly, Rink
amide aminomethyl resin was prepared (28), and the peptide
was elongated using a CEM Liberty microwave peptide synthe-
sizer (CEM Corp., Matthews, NC) using 5% (w/v) piperazine
containing 0.1 M 6-chlorobenzatriazole inN,N-dimethylforma-
mide as Fmoc deblocking reagent and O-(6-chlorobenzotria-
zol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophos-
phate, and N,N-diisopropylethylamine as coupling reagents
usingmicrowave settings as described previously (29). The pep-
tides were cleaved from the resin with concomitant removal of
side chain protecting groups with 94.0% trifluoroacetic acid,
1.0% triisopropylsilane, 2.5% water, and 2.5% 2,2-(ethylene-
dioxy)diethanethiol (v/v/v/v) for 2–3 h, precipitated with cold
diethyl ether, recovered by centrifugation, dissolved in 50%
aqueous acetonitrile containing 0.1% trifluoroacetic acid, and
lyophilized. The crude peptideswere dissolved in 0.1MTris (pH
8.1) at a concentration of 1 mg/ml, and the oxidation (disulfide
formation) was allowed to proceed at room temperature open
to air. Monitoring by reverse phase HPLC and/or LC-MS indi-
cated that the reactionwas typically complete within 1 day. The
solution was acidified to pH 2with 5 MHCl, purified directly by
semipreparative reverse phaseHPLC using a C18Gemini (Phe-
nomenex, Torrance, CA) column (10 250 mm) at a flow rate
of 5 ml/min, and eluted using an appropriate gradient based on
the analytical HPLC profile. Fractions containing the pure pep-
tide were identified by electrospray mass spectrometry and/or
HPLC, pooled, and lyophilized. All peptides were95% pure as
judged by integration of the HPLC chromatogram at 210 nm,
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and peptide masses were confirmed by electrospray mass
spectrometry.
cAMP Assays—We selected the mutants to study based on
the boundaries of the ECLs according to our homology model
of the calcitonin gene-related peptide (CGRP) receptor (CLR/
RAMP1) (26, 30). CLR is predominantly Gs-coupled, so we
characterized AM-stimulated cAMP signaling of alanine (or
leucine, where natively alanine) mutants of CLR complexed
with either RAMP2 or RAMP3. cAMP assays were performed
as described previously using 1 mM isobutylmethylxanthine
and a 15-min cell stimulation period (31). cAMP was then
quantified using ALPHAscreen on a JANUS automated work
station (PerkinElmer Life Sciences).
Analysis of Cell Surface Expression of Mutants by ELISA—
CLR, RAMP2, and RAMP3 are inefficiently expressed on their
own at the cell surface (32). However, when CLR is expressed
with either RAMP, a functional AM1 or AM2 receptor is trans-
located to the cell surface. We determined expression levels of
WTCLR/RAMP2 andCLR/RAMP3 heterodimers and cell sur-
face expression of themutant receptors as described previously,
by measuring HA-CLR (33, 34). Due to the RAMP-dependent
effects observed, we first ensured that each RAMP was capable
of producing equivalent HA-CLR translocation to the cell sur-
face: HA-CLR cell surface expression with (A490  A650/595)
untagged RAMP1, 4.32  0.31 (n  3); Myc-RAMP1, 4.16 
0.22 (n  3); untagged RAMP2, 2.81  0.42 (n  3); FLAG-
RAMP2, 3.08  0.38 (n  3); or untagged RAMP3, 2.96  0.36
(n3) (no significantdifferencesbyone-wayanalysis of variance).
Thus, RAMP-specific effects of CLR mutations are unlikely to be
due to an alteration in receptor density at the cell surface.
Radioligand Binding—AMbinding assays were performed as
described previously, displacing 125I-AM(13–52) with unla-
beled AM (22).
Data Analysis—All experiments were independently repli-
cated at least three times, with two or three technical replicates
in each experiment. Data analysis for cAMP assays was per-
formed in GraphPad Prism version 6 (GraphPad Software, La
Jolla, CA). Concentration-response curves were initially fitted
to a four-parameter logistic equation; in all cases, the Hill slope
was not significantly different from unity. Consequently, this
was constrained to equal 1, the data were refitted to a three-
parameter logistic equation, and pEC50 values were obtained.
In order to determine Emax values for the mutant receptor
curves, the data were normalizedwith respect to the fittedmin-
imum and maximum of theWT curve. The combined normal-
ized data sets were generated by combining the mean of the
data points from the curves of each individual experiment.
Variations in pEC50 between WT and mutant receptors were
analyzed for statistical significance using an unpaired t test on
the values obtained before curve normalization (*, p 0.05; **,
p 0.01; ***, p 0.001). Emax values expressed as a percentage
of WT were analyzed similarly. A 	log pEC50 of 0.5 and a
30% Emax difference (compared with WT) coupled to signif-
icance at the p 0.05 level were used to identify residues with
an unambiguous effect.
To further identifymutants that discriminated betweenAM1
and AM2 receptors, the differences in relative activity (RA)
between the WT and mutant receptors were considered (35).
The log(RA) for each mutant and correspondingWT were cal-
culated as log(mutant Emax/mutant EC50) and log(WT
Emax/WT EC50). The mutant value was subtracted from the
WT value to obtain	log(RA).	log(RA) values different from 0
were identified using multiple t tests with the false discovery
rate set at 1%; differences between 	log(RA)at the AM1 recep-
tor and AM2 receptor were investigated by a two-way analysis
of variance followed by Sidak’s multiple comparison test to
compare individual means. Radioligand binding was analyzed
in GraphPad Prism version 6 to a three-parameter logistic
equation to obtain the pIC50 and maximum specific binding.
For ELISA, values were normalized to WT HA-CLR/RAMP
as 100% and empty vector-transfected cells as 0%. Statistical
significance between WT and mutants was determined using
the 95% confidence interval.
AM Peptide Structure Model—The AM peptide structure
(Fig. 1) was modeled from the known structures of its compo-
nent parts (the disulfide-bonded region, the helical region, and
the ECD region). The key stages in this modeling involved (i)
the use of an in-house multiple-reference sequence alignment
method tailored for aligning helices with low sequence identity
(36) and (ii) the comparative modeling capabilities of PLOP
(37). There is little structural information for full-length AM in
its receptor-bound conformation, making structure-based
sequence alignments difficult. Moreover, class BGPCR peptide
ligands appear to lie in a number of distinct groups (38), so
sequence alignment is not trivial. Consequently, separate align-
ments of the glucagon, GLP-1, PTH, and AM sequences were
generated by ClustalX (39). The helical region of the AM pep-
tide homologs, as indicated by the NMR structure (PDB code
2L7S) (40), was aligned to those of the equivalent helical region
in the glucagon/GLP-1/PTH family of peptides using an in-
house multiple-reference method tailored for aligning helices
with low sequence identity (36) that is a development of the
methods of reference (41). The alignment is given in Fig. 1A; the
alignment scores shown in Fig. 1B (and Fig. 1C) give strong
support for the proposed alignment over the only plausible
alternative involving a shift left of the AM helix by 4 positions.
The AM/CLR/RAMP2 (PDB code 4RWF) ECD (21), the GLP-
1/exendin-4 structure (PDB code 3C59) (42), and the glucagon
model structure (43) were structurally aligned using the
SALIGN module of MODELER (44) (Fig. 1D), from which a
template was constructed using Asp35–Tyr52 from the AM
x-ray structure and Thr7–Tyr13 of the glucagon model peptide
structure, which was preferred over the corresponding (Thr7)-
Asp9-Gln13 of exendin-4 because the angle was more appropri-
ate for peptide binding to the TMbundle. Themissing loopwas
inserted using the comparative modeling, loop modeling, and
minimization capabilities of PLOP (37) based on the alignment
in Fig. 1F. The N terminus, taken fromWoolley et al. (26), was
added by structural alignment of the common helical domain
using VMD (45), again using the alignment in Fig. 1A. The
resulting peptide structure of AM(15–52) (structurally aligned
to the CLR ECD) is shown in Fig. 1E.
AM1 and AM2 Receptor Models—Comparative AM1 and
AM2 receptormodelswere generated usingMODELER version
9.12 (44), essentially from two x-ray structures, namely the AM
CLR-RAMP2 ECD complex (21) (PDB code 4RWF) and the
RAMP Effects on Adrenomedullin Receptors
MAY 27, 2016•VOLUME 291•NUMBER 22 JOURNAL OF BIOLOGICAL CHEMISTRY 11659
glucagon receptor (GCGR) TM domain (43) (PDB code 4L6R).
The GCGR was preferred over the corticotropin-releasing fac-
tor 1 receptor (CRF1R) TM structure because of its overall con-
formation and compatibility with the full GCGR model (43),
but part of the superior quality CRF1R structure (as denoted by
ERRAT (46)) was used in subsequent refinement. In addition,
model structures for the full GCGRmodel (43) containing only
Ser8–Asp15 of glucagon (c.f. Fig. 1D), the full-length AM pep-
tide (Fig. 1E), CGRP(1–7) docked to an active model of CLR
(26), and amodel of the RAMP1TMhelix docked to TM7were
used (Fig. 2). The active character of the model was also
imposed by including TM5-6 of an active CLR model derived
from the 2-adrenergic receptor active complex (47); this tem-
plate also contained the C-terminal peptide of theG protein, Gs
(Arg373–Leu394). Each of these structural templates contained
information on part but not all of the desired structure and was
linked via a global alignment (Fig. 3). In addition, we also
included short N- and C-terminal extensions (6 and 5 residues,
respectively) to the RAMP TM helix and the RAMP ECD to
prevent the linker between them from becoming entangled in
the bulk of the receptor. Within this alignment, the position of
the gap in the CLR sequence between the ECD and TM1 rela-
tive to the longer human glucagon receptor sequence was
determined by analysis of gaps in similar subsets within the
FIGURE 1. Modeling the AM peptide. A, selected class B peptide alignments. Homologs of each of PTH, glucagon, and GLP-1 were aligned against AM
homologs in a multireference profile alignment, as described by Lock et al. (36), over the helical region denoted X. B, the multireference alignment scores.
Alignment 0, corresponding to the alignment inA, has the highest score; the next highest score (alignment4) corresponds tomoving theAMhelix 4 residues
to the left, but this alternative score is low.C, as forBbutmissingPTH (red), glucagon (green), orGLP-1 (cyan); the results arepresentedas a control.D, a structural
alignment of CLR (light green surface, schematic)/AM(35–52) (dark green schematic), GLP-1R (orange schematic)/exendin-4 (wheat/orange schematic), andGCGR
(yellow schematic)/glucagon Thr7–Tyr13 (yellow). The AM(23–52) comparative modeling template was taken from AM(35–52) and glucagon Thr7–Tyr13. The
exendin-4 is largelywheat-colored, but the region corresponding to Thr7–Tyr13 of glucagon is orange. E, the final AM(16–52) structure (black schematic, used as
one of the templates for modeling the AM receptor) structurally aligned to the CLR ECD. The various components of AM are shown as color-coded transparent
spheres: yellow, carbon atoms (disulfide-bonded loop); green, carbon atoms (helix); cyan, carbon atoms (loop); blue, carbon atoms (from the original x-ray
structure). The final structure is very similar to this initial template structure. F, the alignment for the comparative modeling of AM(23–52).
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glucagon multiple-sequence alignment (48). Two thousand
models were generated, and the model having the lowest (best)
DOPE score was chosen for further refinement. ECL1 was
refined usingMODELER fromTM1–4 of a CLRmodel derived
from the CRF1R structure in which variability (30, 49, 50) was
used to orient the CLR ECL1 helix, as in a recent GLP-1 recep-
tormodel (51). The ECLs and the RAMP linker (here defined as
the region connecting the extracellular helical domain and the
TM helix (i.e. residues Val134–Leu147 for RAMP2 and Val106–
Leu119 for RAMP3)) were refined using PLOP, which has been
shown to performwell inGPCR loopmodeling (37); this refine-
ment removed any bias introduced by the extensions. The final
models were minimized using PLOP (37).
Druggability was assessed using the PockDrug (52, 53) and
DoGSiteScorer Web servers (54); pocket hull volumes (which
include atoms within the druggable binding pockets) were also
determined using PockDrug; distances were measured using
the PyMOL Molecular Graphics System (version 1.7.4;
Schro¨dinger, LLC, New York), which was also used for image
generation. The models are available as supplemental models 1
and 2.
Results
Receptor Cell Surface Expression—The cell surface expres-
sion levels of theWT AM1 and AM2 receptors were not signif-
icantly different (see “Experimental Procedures”). The cell sur-
face expressionof allmutant receptors showedvery fewsignificant
differences compared withWT (Table 1). L351A and E357ACLR
showed an 80% reduction of cell surface expression with both
RAMPs, suggesting that these mutations caused the receptors to
fail quality control processesprior to reaching thecell surface. Fur-
ther data for these mutants is not discussed.
Functional Analysis of Receptor Mutations—We assayed a
total of 68 CLR mutants with RAMP2 and with RAMP3. All
results are reported in Tables 2 and 3. cAMP data for selected
mutants, which illustrate a breadth of effects, are shown in Figs.
4 and 5. The mutations could in principle change either the
affinity of binding of AM or its ability to activate the receptor
(efficacy). Efficacy can be estimated to some extent from Emax,
but this is limited by receptor reserve. Furthermore, for many
mutants, we cannot measure affinity directly because the only
radioligand available to us is the agonist, 125I-AM, which will
not give detectable binding once its affinity goes below around
10 nM. The EC50 describes potency but does not provide a ready
means for identifyingmutants that alter efficacy as well as affin-
ity. Accordingly, we have used 	log(RA) (see “Experimental
Procedures”) as a simple parameter to characterize the effect of
the mutations in functional assays; where appropriate, we sup-
plement this with observations on Emax or EC50. Using this, we
describe below our major observations, categorized according
to the effect of the mutation. We have also conducted radioli-
gand binding assays using 125I-AM on selected mutants to pro-
vide additional information (Fig. 6).
There was a core subset of six residues that were important
for the function of the AM1 and AM2 receptors (Ala199, Asp280,
Ile284, Thr288, Phe349, and Tyr365), producing shared changes in
pEC50, Emax or 	log(RA). We define all of these six as having
common effects (Fig. 4). These residues are situated within
ECL2 and the TM6-ECL3-TM7 juxtamembrane region, along
with A199L in TM2.
A further 10 mutations had an effect at both AM receptors,
but the nature of the effect differed between the two receptors
(Leu195, Val198, Cys212, Lys213, Arg274, Trp283, Ile352, Pro353,
Trp354, andAla361). These are defined as residueswith common
but differential effects (Fig. 5). L195A in TM2, C212A at the
ECL1-TM3 boundary, and P353A at the TM6-ECL3 boundary
abolished AM-mediated cAMP production at the AM1 recep-
tor, whereas K213A reduced this by 80%. For C212A, there was
a trend for the radioligand binding to be modestly reduced at
the AM1 receptor but enhanced at the AM2 receptor, consis-
tent with a differential effect of this mutation at both receptors
(Fig. 6). The corresponding mutations in the AM2 receptor
were less deleterious. I352A and W354A mutations gave very
similar changes in 	log(RA), and radioligand binding shows a
FIGURE 2. The template structure of RAMP docked to an active model of
CLR. The template structure (gray) was generated as follows. The length of
the TMhelix for RAMP1 is given as 21 residues by UniProt, but this is too short
for a tilted helix to span the membrane. Consequently, for RAMP1, helices of
lengths 26, 28, and 30 residues were constructed using Maestro, commenc-
ing at Ser117, Pro115, andAsp113, respectively. For RAMP2, helices of length 24,
26, and 28 residues were constructed, commencing at Asp144, Pro142, and
Asp140, respectively. For RAMP3, helices of lengths 25, 26, and 28 residues
were constructed, commencing at Asp116, Pro115, and Asp113, respectively.
Theheliceswere dockedusing theCluspro, PatchDock, and SwarmDock serv-
ers to two active models of the CLR transmembrane helical bundle (six dock-
ing experiments) (30, 65–67); the active explicit membrane CLR model has
been shown to be in very good agreementwith the x-ray crystal structures of
the GCGR and CRF1R (26). Results from each server that were not compatible
with the membrane topology were eliminated, and the remaining viable
solutions were clustered. Representative solutions were then refined and
rescored using the FireDock server (so that poses generated by the different
servers are treated equally) (68, 69). The three best poses (on the basis of
lowest energy and geometry consensus) were then docked using Rosetta-
Dock (70–72). The consensus result showed apreference for the helix to dock
to TM7 of the active receptor, in agreement with experimental results that
indicate an interaction with TM6/7 (60). The active AM1 (light blue) and AM2
(wheat)model TMdomains, the inactiveGCGR (yellow), andTM1–TM4of inac-
tive CRF1R (orange) structures, superimposed over TM1, TM2, TM3, the top of
TM4 (because of irregularities in the GCGR x-ray structure; c.f. CRF1R), and
TM7, are also shown. TM5, TM6, and the top of TM7 were omitted from the
fitting because of differences in active and inactive structures in this region.
All root mean square deviations were2 Å.
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similar reduction in specific binding for I352Aat both receptors
(Fig. 6). However, in both cases, the effects on Emax were more
marked at the AM1 receptor, so these have been included as
common but differential residues. Whereas V198A showed
only a small difference in 	log(RA), it significantly increased
Emax at the AM2 receptor but not the AM1 receptor. A361Lwas
a difficult mutant to characterize; whereas the Emax is reduced
at both the AM1 and AM2 receptors, the changes in 	log(RA)
were of opposing directions.
Five of the 68 mutants had more pronounced differential
effects between the receptors. These are referred to as differen-
tial residues (Fig. 5). A271L, Y277A,Y278A,N279A, andC282A
all increased 	log(RA) at the AM1 receptor but had no signifi-
cant effect at theAM2 receptor. ForY277A, radioligand binding
was substantially reduced at the AM1 receptor but retained at
the AM2 receptor, consistent with a differential effect of this
mutation at both receptors. C282A binding was unchanged at
the AM1 receptor but showed a trend to be enhanced at the
AM2 receptor (Fig. 6). In addition, for Y367A, we observed a
decrease in pEC50 at the AM2 receptor but no effect at the AM1
receptor.Although the differences inEmax at either receptor did
not reach statistical significance, the effectwas oppositewith an
increase at the AM2 receptor and a decrease at the AM1 recep-
tor. This is an atypical mutation because the effect is greater at
the AM2 receptor.
Overall Description of the AM1 and AM2 Receptor Models—
To assist in data interpretation, we generated AM1 and AM2
receptor models, which we understand to be the first models of
a full-length GPCR in complex with a RAMP (Fig. 7, A and B).
The RAMPTMhelix lies between TM6 and TM7 of CLR with-
out inducing strain in the sequence joining the RAMP ECD to
the TM (the RAMP linker). The predicted arrangement of the
TM helices forms a conical pocket (the peptide binding site) into
which the disulfide loopof theAMpeptide docks (Fig. 7,C andD).
ECL boundaries are very similar to those in the CGRP receptor
(26) and those of other class B GPCR x-ray structures (43, 50).
In the AM peptide model, residues 15–21 form a disulfide
loop, residues 22–31 are helical (40), and residues 35–52 adopt
the largely non-helical structure bound to the ECD of the AM1
receptor (21); the remaining residues (positions 33–41) form a
loop, creating the AM structure. The model therefore rational-
izes previouswork on the degree of helicitywithinAM(Fig. 1E).
The RAMP2 linker (residues Val134–Leu147 between the ECD
and the TM region) is displaced relative to that of RAMP3, lies
closer to the peptide binding pocket than does RAMP3, and is
predicted by the models to interact with ECL3 and the top of
TM7 of CLR (Figs. 7 and 9).
The electrostatic potential of AM in its proposed bound con-
formation (Fig. 8, A and B) is largely positive because AM car-
ries a charge of 
4. The electrostatic potential of CLR in the
absence of RAMPandAM is largely positive or neutral (Fig. 8,C
andD). BothRAMP2 andRAMP3 convey an advantage in bind-
ing the positive AM because they switch this potential in the
conical TM pocket and particularly on the ECD to more nega-
tive values, which will aid in binding the positively charged AM
(Fig. 8, E and F). RAMP3 gives rise to the most negative ECD
electrostatic potential.
Detailed Comparison between AM1 and AM2 Receptor
Models—Overall, the ECL2 conformation is similar between
the two models, consistent with the observation that many of
FIGURE 3. The alignment for comparative modeling. The alignment was generated by structural alignment of the templates using the SALIGN module of
MODELERand refinedusing Jalview (73). The residues are color-coded according to their properties as follows:blue, positive; red, negativeor small polar;purple,
polar; green large hydrophobic; yellow, small hydrophobic; cyan, polar, aromatic. This corresponds to the “Taylor” scheme, as implemented in Jalview. The
extracellular loops are denoted by gray shading and the loop number.
TABLE 1
Cell surface expression of AM1 and AM2 receptors expressed as a percentage of the wild type receptor
Data are mean S.E. of n 3–4 individual experiments. *95% confidence interval does not include 100%.
TM2-ECL1-TM3 TM4-ECL2-TM5 TM6-ECL3-TM7
AM1 receptor AM2 receptor AM1 receptor AM2 receptor AM1 receptor AM2 receptor
% % % % % %
L195A 91.2 2.08 81.4 25.9 A271L 118.8 13.2 118.8 20.6 F349A 98.5 11.3 93.9 22.5
T196A 94.9 17.8 90.5 20.1 I272A 115.9 15.6 64.1 23.5 V350A 104.2 8.06 106.5 33.4
A197L 111.4 7.28 85.9 21.2 A273L 112.3 11.6 107.7 6.74 L351A 9.75 3.17* 21.9 12.3*
V198A 105.8 14.1 84.3 19.0 R274A 98.1 17.3 107.2 14.4 I352A 68.9 10.2* 121.2 13.7
A199L 99.8 7.56 136.7 76.6 S275A 77.3 10.1 113.0 25.3 P353A 94.2 8.95 104.0 23.8
N200A 100.1 6.69 48.4 8.62 L276A 73.8 10.2 110.3 21.7 W354A 85.9 9.30 103.7 24.0
N201A 81.9 15.9 38.9 13.4 Y277A 94.0 7.26 132.4 23.0 R355A 114.7 13.0 86.5 11.8
Q202A 94.8 1.92 83.2 10.2 Y278A 75.8 27.6 154.1 27.1 P356A 101.3 3.59 87.6 13.3
A203L 95.5 9.67 72.1 18.4 N279A 97.0 6.30 96.8 17.0 E357A 17.2 4.85* 15.1 9.97*
L204A 98.3 2.83 114.0 15.8 D280A 155.8 68.9 126.1 16.8 G358A 108.2 7.72 85.7 9.81
V205A 117.3 6.49 88.7 13.1 N281A 108.1 2.90 119.9 2.97 K359A 99.6 2.63 76.3 11.9
A206L 92.9 8.45 91.4 13.1 C282A 64.9 16.8 100.7 11.7 I360A 85.8 3.81 82.5 7.48
T207A 99.9 1.52 82.2 15.5 W283A 107.7 11.9 100.4 13.4 A361L 102.2 3.45 83.1 8.75
N208A 98.6 1.02 111.5 18.4 I284A 67.1 8.80 107.6 26.2 E362A 103.8 6.14 75.4 4.93
P209A 100.3 5.96 118.6 34.5 S285A 86.1 20.2 124.7 31.6 E363A 103.0 2.74 75.6 4.22
V210A 100.4 5.63 88.2 15.0 S286A 93.2 12.9 104.7 15.0 V364A 94.0 2.74 100.5 12.5
S211A 97.5 3.73 95.4 18.7 D287A 77.4 13.4 107.3 7.33 Y365A 92.5 6.21 121.3 24.5
C212A 119.0 25.1 93.6 22.1 I288A 94.8 23.5 90.0 7.14 D366A 107.5 4.33 103.1 19.4
K213A 131.3 33.1 84.3 21.3 H289A 93.1 16.2 95.7 12.9 Y367A 110.0 2.03 106.2 16.4
V214A 87.5 9.71 86.6 17.9 L290A 102.5 2.45 98.6 7.36 I368A 90.8 15.2 118.6 24.7
S215A 86.2 10.7 84.5 17.3 L291A 103.5 7.54 130.8 10.3 M369A 82.8 13.9 108.2 25.1
Q216A 95.7 2.47 124.9 23.7 Y292A 83.5 7.47 176.5 40.6
F217A 101.8 7.45 99.0 12.0 I293A 99.2 1.44 107.9 12.5
I294A 103.2 14.7 102.8 29.8
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TABLE 2
Pharmacological parameters of cAMP accumulation for the AM receptors when stimulated by AM
*, p 0.05; **, p 0.01; ***, p 0.001 versusWT, by unpaired t test except for 	log(RA), where the comparison is between AM1 and AM2 receptors by two-way analysis
of variance followed by Sidak’s multiple comparison test. Common residues are in boldface type, common-differential residues are in boldface italic type, and differential
residues are in italic type.
AM1 receptor AM2 receptor
WT pEC50 Mutant pEC50 Log pEC50 Emax (%WT) Log(RA) n WT pEC50 Mutant pEC50 Log pEC50 Emax (%WT) Log(RA) n
TM2
L195A 9.28 0.10 6 2.00 No curvea - 5 9.11 0.16 7.40 0.17*** 1.71 65.3 11.3* 1.90 0.25b,c 5
T196A 8.94 0.13 8.95 0.03 0.01 119.5 23.5 0.09 0.16 3 8.90 0.19 8.66 0.19 0.24 116.5 20.4 0.17 0.28 3
A197L 8.91 0.25 8.61 0.13 0.30 90.4 6.32 0.34 0.28 4 9.19 0.14 8.90 0.11 0.29 136.9 30.1 0.15 0.20 3
V198A 9.13 0.11 8.32 0.15*** 0.81 74.5 12.2 0.94 0.20b 7 9.41 0.14 8.64 0.19* 0.77 160.6 26.16* 0.56 0.25 3
ECL1
A199L 9.14 0.12 8.10 0.23** 1.04 55.4 8.56** 1.29 0.28b 6 9.29 0.16 7.98 0.20** 1.31 88.6 9.46 1.36 0.26 4
N200A 9.11 0.16 9.55 0.10 0.44 80.9 17.4 0.35 0.21 3 9.16 0.14 9.57 0.22 0.41 69.3 3.75*** 0.25 0.26 3
N201A 9.02 0.16 8.70 0.18 0.32 89.8 4.70 0.37 0.24 4 9.14 0.10 8.50 0.22 0.64 133.3 36.3 0.52 0.27 3
Q202A 9.00 0.07 9.15 0.09 0.15 82.9 11.1 0.069 0.13 4 9.14 0.10 9.30 0.13 0.16 184.4 40.3 0.43 0.19 3
A203L 9.27 0.08 9.14 0.08 0.13 82.5 6.92* 0.21 0.12 5 9.14 0.10 9.14 0.08 0.00 207.5 57.6 0.32 0.17 3
L204A 8.93 0.04 8.62 0.03** 0.31 98.9 5.36 0.31 0.06 3 9.42 0.29 8.89 0.16 0.53 145.7 24.9 0.37 0.34 3
V205A 9.10 0.06 8.67 0.14* 0.43 79.9 16.8 0.53 30.18 4 9.42 0.29 9.10 0.10 0.32 135.2 34.7 0.19 0.32 3
A206L 9.30 0.08 8.93 0.09* 0.37 113.3 17.8 0.32 0.14 4 9.42 0.29 9.33 0.14 0.09 118.2 43.4 0.02 0.36 3
T207A 9.10 0.06 9.08 0.16 0.02 87.6 2.59* 0.077 0.17 4 9.41 0.05 9.21 0.05 0.20 81.7 14.2 0.29 0.10 4
N208A 8.97 0.06 8.73 0.10 0.24 84.9 10.7 0.31 0.13 5 9.41 0.05 8.82 0.04*** 0.59 105.4 39.8 0.57 0.18 4
P209A 8.99 0.02 8.63 0.09** 0.36 109.0 13.4 0.32 0.11 4 9.41 0.05 8.88 0.15* 0.53 107.2 40.2 0.50 0.23 4
V210A 9.19 0.06 9.03 0.14 0.16 74.9 5.17** 0.29 0.16 4 9.25 0.10 9.03 0.08 0.22 133.3 18.9 0.10 0.14 3
S211A 9.09 0.10 8.97 0.11 0.12 103.5 12.1 0.11 0.15 5 9.25 0.10 9.10 0.03 0.15 143.8 66.6 0.01 0.23 3
TM3
C212A 9.04 0.21 6 2.00 No curve - 6 9.20 0.07 8.59 0.15** 0.61 91.51 18.7 0.65 0.19c 6
K213A 9.22 0.09 8.05 0.09*** 1.17 21.2 7.38*** 1.84 0.204b 5 9.14 0.08 8.31 0.07*** 0.83 97.7 8.43 0.84 0.11b 5
V214A 9.11 0.12 9.01 0.17 0.10 89.4 7.11 0.15 0.21 5 9.14 0.11 9.14 0.17 0.00 98.7 9.12 0.01 0.21 4
S215A 8.90 0.12 8.81 0.06 0.09 99.3 1.87 0.093 0.13 4 9.21 0.12 9.22 0.21 0.01 111.4 13.8 0.06 0.25 3
Q216A 9.00 0.12 9.60 0.24 0.6 100.2 20.1 0.60 0.28 5 9.45 0.14 9.42 0.15 0.03 84.9 7.41 0.10 0.21 3
F217A 9.19 0.03 8.82 0.11** 0.37 97.3 18.8 0.38 0.14 7 9.41 0.11 8.99 0.15 0.44 100.3 17.0 0.42 0.20 5
TM4
A271L 9.27 0.14 8.33 0.23** 0.94 71.4 9.83* 1.09 0.28 5 9.41 0.09 9.16 0.18 0.25 98.8 33.7 0.26 0.25 5
I272A 9.31 0.18 9.65 0.18 0.34 151.6 87.8 0.52 0.36 6 9.41 0.09 9.42 0.08 0.01 94.3 18.1 0.02 0.15 5
A273L 8.96 0.14 8.91 0.09 0.05 147.4 42.7 0.12 0.215 4 9.26 0.10 9.15 0.09 0.11 100.4 9.90 0.11 0.14 4
R274A 9.51 0.18 7.32 0.14*** 2.19 17.7 5.01*** 2.94 0.26b 5 9.24 0.08 8.24 0.11*** 1.00 31.6 10.1*** 1.50 0.19b*** 5
ECL2
S275A 9.29 0.13 9.39 0.21 0.10 103.3 18.2 0.11 0.26 5 9.30 0.15 9.23 0.22 0.10 114.9 22.6 0.01 0.28 5
L276A 9.29 0.17 9.23 0.15 0.06 96.8 18.0 0.074 0.24 4 9.30 0.15 9.34 0.16 0.04 70.2 12.4 0.11 0.23 4
Y277A 9.51 0.13 8.79 0.19* 0.72 33.3 8.98*** 1.20 0.26b 7 9.35 0.09 9.23 0.05 0.12 113.7 21.2 0.06 0.13** 5
Y278A 9.54 0.13 8.45 0.13*** 1.13 55.9 9.33*** 1.34 0.20b 7 9.34 0.12 8.92 0.09 0.42 106.0 29.5 0.39 0.19 5
N279A 9.04 0.10 8.53 0.31 0.25 21.7 25.9 1.17 0.614 4 9.45 0.10 9.17 0.10 0.28 95.6 11.8 0.30 0.15 4
D280A 9.29 0.08 8.39 0.08*** 0.90 73.6 7.61** 1.03 0.12b 6 9.56 0.07 8.31 0.26** 1.25 93.7 19.0 1.28 0.28b 5
N281A 9.32 0.08 9.26 0.10 0.06 128.7 16.9 0.05 0.14 5 9.64 0.10 9.44 0.19 0.20 143.9 16.7 0.04 0.22 4
C282A 9.09 0.05 8.15 0.21** 0.94 48.5 10.2*** 1.25 0.23b 6 9.10 0.11 8.88 0.18 0.22 117.3 16.7 0.15 0.22* 5
W283A 9.19 0.13 6.96 0.17*** 2.23 25.9 11.7*** 2.82 0.29b 5 9.54 0.08 7.96 0.10*** 1.58 71.7 27.5 1.72 0.21b* 5
I284A 8.97 0.11 6.75 0.35** 2.02 35.2 7.25*** 2.67 0.38b 5 9.08 0.12 7.36 0.21*** 1.72 51.8 18.4** 2.01 0.29b 5
S285A 9.33 0.07 9.02 0.08 0.31 196.7 113.9 0.02 0.27 4 9.60 0.09 9.37 0.11 0.23 157.7 52.8 0.03 0.20 5
S286A 9.16 0.27 9.31 0.20 0.15 99.2 16.8 0.15 0.34 4 9.45 0.18 9.66 0.11 0.19 71.4 26.4 0.06 0.26 3
D287A 9.26 0.05 9.51 0.47 0.25 105.3 34.5 0.27 0.49 4 9.31 0.05 9.12 0.12 0.19 104.5 18.8 0.17 0.15 4
T288A 9.15 0.13 8.37 0.05*** 0.78 51.4 3.32*** 1.07 0.14b 4 9.60 0.09 8.97 0.11*** 0.63 78.46 14.6 0.74 0.16 4
H289A 9.09 0.04 9.12 0.13 0.03 118.7 8.74 0.10 0.14 4 9.58 0.26 9.74 0.25 0.16 298.8 143.9 0.64 0.42 5
L290A 8.96 0.14 8.83 0.09 0.13 190.9 84.2 0.15 0.25 4 9.26 0.09 8.97 0.08 0.29 94.4 13.8 0.32 0.14 3
L291A 9.09 0.04 8.62 0.14* 0.47 136.7 45.1 0.33 0.20 4 9.18 0.12 8.83 0.15 0.35 125.1 32.2 0.25 0.22 6
TM5
Y292A 8.96 0.14 8.54 0.06* 0.42 91.2 18.9 0.46 0.18 4 9.32 0.10 8.67 0.17* 0.65 135.1 42.2 0.52 0.24 4
I293A 8.97 0.04 9.20 0.07* 0.28 93.2 29.6 0.20 0.16 4 9.01 0.07 9.13 0.02 0.12 121.8 23.1 0.21 0.11 3
I294A 9.09 0.04 8.83 0.21 0.26 147.5 53.5 0.09 0.26 4 9.18 0.12 9.12 0.14 0.06 128.3 19.1 0.05 0.19 5
TM6
F349A 9.01 0.11 8.72 0.11 0.29 21.5 1.81*** 0.96 0.16b 5 9.14 0.05 8.61 0.07** 0.53 24.0 9.13*** 1.15 0.19b 5
V350A 8.86 0.28 8.72 0.07 0.14 63.7 4.94*** 0.34 0.29 4 9.14 0.05 8.87 0.34 0.27 65.8 17.3 0.45 0.36 4
L351A 9.15 0.10 No curve 3 No Curve - 4 9.09 0.06 No Curve 3 No Curve - 3
I352A 9.01 0.11 8.28 0.27* 0.73 37.7 9.87*** 1.15 0.31 5 9.40 0.08 8.46 0.10*** 0.94 86.9 30.1 1.00 0.20b 5
P353A 9.07 0.13 No Curve 3 No Curve - 5 9.42 0.09 8.49 0.06*** 0.91 47.1 9.19*** 1.26 0.14b,c 5
W354A 9.29 0.06 8.50 0.12*** 0.79 37.2 7.38*** 1.22 0.16b 5 9.40 0.08 8.59 0.13*** 0.81 112.4 17.5 0.76 0.17b 5
R355A 9.13 0.08 9.50 0.12* 0.37 80.4 7.97* 0.27 0.15 4 9.27 0.26 9.89 0.03 0.62 91.0 18.6 0.58 0.28 3
P356A 9.15 0.10 8.99 0.10 0.16 40.4 3.66*** 0.55 0.15 4 9.34 0.20 9.12 0.29 0.22 60.0 23.1 0.44 0.39 4
ECL3
E357A 9.00 0.08 No Curve 3 No Curve - 4 9.23 0.26 No Curve 3 No Curve - 3
G358A 9.09 0.11 9.06 0.11 0.03 104.5 5.46 0.01 0.16 4 8.79 0.14 8.84 0.27 0.05 80.9 55.3 0.04 0.42 3
K359A 9.09 0.11 9.19 0.10 0.10 107.5 4.28 0.13 0.15 4 9.27 0.26 9.30 0.14 0.03 75.9 4.14*** 0.09 0.29 3
I360A 9.13 0.18 8.99 0.08 0.14 83.3 9.47 0.22 0.20 4 8.79 0.14 8.79 0.29 0.00 82.8 35.9 0.08 0.37 3
A361L 9.10 0.18 9.52 0.15 0.42 77.8 6.34* 0.31 0.24 4 9.15 0.13 8.62 0.40 0.53 67.4 12.4* 0.70 0.43 4
E362A 9.10 0.18 9.00 0.07 0.10 98.0 6.53 0.11 0.19 4 9.22 0.10 8.91 0.10 0.21 241.7 76.1 0.07 0.20 3
E363A 9.00 0.08 8.87 0.15 0.13 93.9 13.5 0.16 0.18 4 9.22 0.10 8.99 0.11 0.23 217.7 72.3 0.11 0.21 3
V364A 9.00 0.08 8.84 0.13 0.16 84.3 8.49 0.23 0.16 4 9.16 0.09 9.14 0.14 0.02 83.2 3.57 0.10 0.17 4
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the residues with common cAMP effects are located in this
invariant region and may contact the peptide (Fig. 9A). Resi-
dues with common but differential effects at each receptor also
have largely similar orientations within the models (Fig. 9B).
These residues are also mostly situated at the tops of the TM2
(Leu195 and Val198), TM3 (Cys212 and Lys213), and TM6 (Ile352,
Pro353, and Trp354). Along with the common residues Ala199
and Phe349 and common but differential Arg274, these form a
network around the top of the TMhelices. Differential residues
Tyr277 and Cys282 are situated in ECL2 (Fig. 9C). Cys212, Tyr278,
Cys282, and Lys213 do not appear to change their orientation
significantly between the two AM receptors (Fig. 9, B and C).
Lys213 remains parallel to the Cys212–Cys282 bond, facing
Tyr278 in both structures. Tyr277 moves outward in the AM2
receptor and points away from the peptide binding pocket, thus
changing its environment (Fig. 9C).
The most striking conformational difference between the
AM1 and AM2 receptor models is the dramatic change in the
FIGURE 4. Examples of mutants with common effects on cAMP production in both the AM1 and AM2 receptors. Concentration-response curves are
combined normalized data S.E. (error bars) for at least three individual experiments.
TABLE 2—continued
AM1 receptor AM2 receptor
WT pEC50 Mutant pEC50 Log pEC50 Emax (%WT) Log(RA) n WT pEC50 Mutant pEC50 Log pEC50 Emax (%WT) Log(RA) n
TM7
Y365A 9.09 0.11 8.83 0.11 0.26 68.9 6.54** 0.42 0.16 4 9.02 0.12 8.51 0.33 0.51 65.2 0.85** 0.70 0.35 3
D366A 8.97 0.08 8.76 0.15 0.21 69.9 15.7 0.37 0.19 4 9.17 0.11 9.19 0.30 0.02 105.7 23.8 0.04 0.33 3
Y367A 9.16 0.10 9.11 0.03 0.04 70.0 6.69 0.20 0.11 3 9.28 0.17 8.61 0.16* 0.67 163.7 32.8 0.46 0.25 3
I368A 9.06 0.12 9.06 0.08 0.00 77.3 12.6 0.11 0.16 4 9.28 0.17 9.39 0.25 0.11 251.1 120 0.51 0.37 3
M369A 9.06 0.12 9.06 0.13 0.00 185.1 28.0* 0.27 0.19 4 9.28 0.17 8.82 0.27 0.46 295.7 103.1 0.01 0.35 3
a No curve, cAMP response was too low for a concentration-response curve to be fitted (pEC50 and 	log pEC50 are denoted as6 and2).
b Different from 0, as assessed by multiple t tests with the false discovery rate set to 1%.
c 	Log(RA) values where only the AM2 receptor was active.
TABLE 3
Pharmacological parameters for 125I-AM(13–52) binding for WT or mutant AM receptors
Common-differential residues are bold italics and differential residues are italics. Maximum specific binding is total binding (125I-AM13–52 bound in the absence of
competing ligand) minus the non-specific binding (125I-AM13–52 bound in the presence of 3 M AM).
AM1 receptor AM2 receptor
pIC50
Maximum specific
binding (%WT) n pIC50
Maximum specific
binding (%WT) n
WT 8.56 0.04 4 8.64 0.07 4
C212A 8.06 0.16 71.7 20.7 3 8.35 0.18 145.5 23.4 3
Y277A 8.46 0.35 34.3 11.1a 3 8.52 0.15 97.4 21.6 3
C282A 8.40 0.15 85.4 24.9 3 8.31 0.29 180.4 46.6 3
I352A 8.56 0.10 43.5 7.0a 3 8.65 0.21 42.2 13.2a 3
a 95% confidence interval does not include 100%.
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position of ECL3 (Fig. 9D). The extracellular end of TM6 forms
a distorted helix as a result of the influence of Pro353, Pro356,
and Gly358. The conformation of ECL3 begins to diverge
between the two models after the common differential residue
Pro353. Trp354 stacks with ECL3 in the AM1 receptor, whereas
in theAM2 receptor it is rotated by 90°,moving it away from the
loop to face the lipid membrane. In the AM2 receptor model,
ECL3 makes extensive contacts with AM, whereas in the AM1
receptor, these contacts are minimal. The cumulative result of
these differences is that distances relevant to the binding site
vary in size (Fig. 9, E and F).
Probing the Model; Differential Peptide Contacts within the
AM1 and AM2 Receptor TM Pockets—The divergence between
the models translates into different transmembrane AM bind-
FIGURE5.Examplesofmutantswith common-differential anddifferential (C282AandY277A)effectsoncAMPproductionbetween theAMreceptors.
WT curves were included in every experiment but are only shown as examples for L195A so that mutant differences between the receptors are not obscured
by these curves in theotherpanels. Thehorizontal line representsmaximal (100%) cAMPaccumulation for theWT receptors. Concentration-response curves are
combined normalized data S.E. (error bars) for at least three individual experiments.
FIGURE 6. 125I-AM(13–52) binding at selected mutants with common-differential and differential (Y277A and C282A) effects in cAMP assays. The
curves are combined normalized data S.E. (error bars) for three individual experiments.
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ing pocket hull volumes of 4874 Å3 for the AM1 receptor versus
3313 Å3 for the AM2 receptor; the shapes of the two pockets
also differ. The disulfide loop (Cys16–Cys21) of the docked AM
peptide is located in the wide mouth of the peptide binding
pocket with the side chain of Phe18 occupying the lower part of
the pocket (Fig. 7D). Visual analysis and loop modeling indi-
cated that Phe18, unlike its neighbors, occupied a more con-
strained pocket in the AM2 receptor than in the AM1 receptor.
Consequently, we examined R17A, F18A, G19A, and T20A
mutations in both the AM1 and AM2 receptors using MOD-
ELER; 100 models were generated, and the model with the best
DOPE score was analyzed. In each case, apart from F18A, there
was an equivalent decrease in the number of contacts (4 Å) in
both AM1 and AM2, but for F18A, there was a bigger decrease
in the number of side chain contacts in the AM1 receptor (from
eight to two) rather than in the AM2 receptor (from six to two).
We therefore proposed that substitution of Phe18 with alanine
would have a greater impact in the AM1 receptor, compared
with the AM2 receptor. Consistent with our hypothesis, an
F18A AM peptide stimulated cAMP production to a lesser
degree at the AM1 receptor (60% decrease in Emax) than at the
AM2 receptor (no change in Emax) (Table 4 and Fig. 10). This
demonstrates that it is possible to engineer ligand-specific
effects at these two receptors.
Small Molecule Druggability of the AM Receptors—We next
analyzed the two receptor binding pockets for their druggabil-
ity for small molecule, orally bioavailable ligands using the
PockDrug and DoGSiteScorer druggability servers (52–54),
which were trained to predict pockets with promising proper-
ties for the design of small molecule druglike ligands. Because
druggability analysis is highly dependent on the cavity detec-
tion (53), we only discuss residues predicted by both servers to
reside in the main helical binding pocket, namely 43 residues
common to the AM1 receptor pocket and 31 for the smaller
AM2 receptor pocket; these consensus residues largely coincide
with the largest subpocket given by DoGSiteScorer. This anal-
ysis showed that the main druggable pocket in the helical
domain of each AM receptor partially overlapped with the pep-
tide binding pocket identified by our models (Fig. 11, A and B).
In both receptors, the druggable pocket includes the hydropho-
bic patch at the top of TM2 (e.g. Leu195), the distal residues of
ECL2 (Trp283–Thr288), and residues on TM3 (e.g. Asp366,
Tyr367, and His370). The druggable pockets extend below the
limits of the peptide binding pocket and include Met223 and
Tyr227 onTM3 for both receptors, but theAM1 pocket includes
other TM3 residues (e.g. Leu220). The druggable pockets also
extend lower on TM6 to include Ile370 and Ile371 for the AM1
receptor. The AM1 pocket includes more residues on TM1 (e.g.
FIGURE 7.Models of the full-length AM receptors. A, AM1 receptor; B, AM2 receptor. Images were generated from an overlay aligning CLR residues 138–394
for both models (root mean square deviation 2.0 Å). Relative sizes and orientations are thus not an artifact of figure generation. C, surface representation of
thepeptidebindingpocketof theAM1andAM2 receptors illustrating the changes in receptor conformationand thepeptidebindingpocket.D, close-up surface
representation of the peptide binding pocket showing the docked AM peptide and its five close receptor neighbors, determined by the models in blue sticks
(AM1 receptor) and yellow sticks (AM2 receptor). Other colors in C and D are as described for A and B.
RAMP Effects on Adrenomedullin Receptors
MAY 27, 2016•VOLUME 291•NUMBER 22 JOURNAL OF BIOLOGICAL CHEMISTRY 11667
Thr145 and His149). Twenty-four residues were unique to the
AM1 receptor, and seven were unique to the AM2 receptor,
indicating that selectivity is possible. Some of the residues listed
as part of the druggable pocket are more accessible than others
(e.g. Phe228 in the AM1 receptor is not obviously accessible in
the absence of induced fit, because it is partially shielded by
Tyr227), but such residues may nevertheless be important in
drug design. The AM1 receptor pocket reaches 14 Å below the
top of ECL3 with drug scores of 0.97 and 0.81, from PockDrug
and DoGSiteScorer, respectively. The AM2 receptor drug-
gable pocket forms a narrow channel and is deeper (partly
because of the ECL3 conformation), with PockDrug and
DoGSiteScorer drug scores of 0.91 and 0.81, respectively;
because the scores are above 0.5, both receptors are pre-
dicted to be druggable.
Discussion
Pharmacological tools to help tease out the relative impor-
tance of each of the twoAMreceptors are needed, but it has not
been apparent how to develop these because both receptors
share the common GPCR, CLR. We report that RAMP2 and
RAMP3confer conformational variation in theCLR juxtamem-
FIGURE 8. The electrostatic potential of AM, CLR, and the AM1 and AM2 receptors. Blue, positive; red, negative; the potential has been contoured
between5 and
5 onto the solvent-accessible surface. A, the electrostatic potential on the face of AM that is exposed as it binds to the CLR ECD; the
electrostatic potential is weakly positive, and the general orientation is as shown in C. B, the electrostatic potential on the ECD-binding surface, as
defined by C; the electrostatic potential is strongly positive. The
4 charge on AM includes the N-terminal amine. C, a representation of AM binding to
the AM1 receptor that can be used to identify the peptide-binding region in D–F: the CLR solvent-accessible surface is blue, the RAMP surface is red, and
the C-terminal peptide of Gs is cyan. The solvent radius was expanded to 2.4 Å to mimic that in D–F. AM is shown in white. D, CLR electrostatic potential.
E, AM1 electrostatic potential. F, AM2 electrostatic potential. The electrostatic potential of the AM1 and AM2 receptors was evaluated in an implicit
membrane using APBS (the Adaptive Poisson-Boltzmann Solver) coupled with apbs_mem version 2.0 and the pdb2PQR server (74–76). The parameters
for the APBSmem calculations were as follows: PARSE atomic charges (77); temperature, 298.15 K; ionic strength, 0.15 mM; protein and membrane
relative dieletric constant, 2.0; relative solvent dielectric, 80; membrane thickness, 40 Å. The grid lengths were 300  300  300 Å with two levels of
focusing; the grid dimensions were 97 97 97 for A and B and 129 129 225 for D–F. The CHARMM-gui was used to assist in placing the receptor
within the membrane (78).
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brane region, yielding distinct binding pockets that may be
tractable for the development of selective pharmacological
tools and future drugs.
OurstudycombinedextensivemutagenesisofCLRwith inde-
pendent modeling studies (i.e. not adjusted to enhance agree-
ment with data tables) that allowed us to effectively interpret
FIGURE9.Receptormodel overlay.Residueswith common (A), common-differential (B), or differential (C) effects are shownas sticks, with oxygenatoms in red
and nitrogen in blue. A, residues Ala199, Asp280, Ile284, and Phe349 have similar side chain and main chain orientations; Tyr365 has side chain rotation of180°
between the two AM receptors. B, residues Lys213, Ile352, and Trp354 have similar main chain but differing side chain orientations. C, Tyr277 shows substantial
movement between the two receptors, whereas Tyr278 shows somemovement butmaintains similar interactions.D, close-up view of TM6-ECL3-TM7 showing
themain residues involved in the change of the ECL3 position (red arrowdenotes change in position). The increasedproximity of RAMP2 to the CLR ECL3 in the
AM1 receptor is clearly visible. AM1 and AM2 receptors are colored as per the figure; the movement of residues between the receptors is shown with arrows. E
and F, juxtamembrane region of the two receptors with distances between residues (dotted lines) in Å. Distances were measured between the same set of C
atoms in both receptors.
TABLE 4
Pharmacological parameters of cAMP accumulation for F18A substituted AM(15–52) versus wild type (WT) AM(15–52) stimulation of the WT
AM1 and AM2 receptors
*, p 0.05; ***, p 0.001. Data analyzed by unpaired t test versusWT.
WTAM(15–52) pEC50 F18A AM(15–52) pEC50 Log EC50 % Emax WT AM(15–52) n
AM1 receptor 8.89 0.13 7.85 0.11*** 1.04 40.3 9.73*** 4
AM2 receptor 8.91 0.24 7.42 0.24* 1.49 101.7 5.26 3
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our complex data set. Recent crystallographic and modeling
studies have generated a consensus conformation for the TM
bundle of the class B GPCRs (26, 43, 50, 55). Crystallographic
studies have so far, however, proved unsatisfactory for deter-
mining the structure for a complete class B GPCR or for the
class B ECL conformation due to the inherent mobility of the
loops. The only structural data on the arrangement of the ECD
of a class BGPCRwith respect to theTMbundle comes froman
electron microscopy study of the GCGR, and this is necessarily
low resolution (56). Although molecular models do not have
the accuracy of x-ray structures, they are nevertheless useful for
providing a framework against which experimental results can
be considered. While it would be unwise to overinterpret any
model, ours is largely consistent with the effects of the
mutagenesis (Table 5) and also successfully predicted the activ-
ity of F18A AM.
We initially compare our AM receptor models with that of
the GCGRmodel structure (43), a canonical class B GPCR that
does not require aRAMP.Themain difference in the receptor is
a 30° change in the orientation of the ECD to a more open
conformation as a result of the constraint created by the RAMP
on the structure of the AM receptor. The orientation of the
ECD is more consistent with the open (i.e. active, agonist-
bound) conformational ensemble of the GCGR (56) than the
closed ensemble because the difference between the centers of
mass of the TM and ECD domains is57 Å, the polar angle  is
similarly 23°, and the projection of the ECD center of mass
onto the membrane plane lies outside of the helical bundle. In
the GCGR, the simulated closed state described by Yang et al.
(56) may well be the inactive conformation, satisfying the pro-
posed ECD-ECL3 interaction proposed by Koth et al. (57), but
in the AM receptors, because the RAMP binds to the peptide-
binding face of the ECD, it is likely to inhibit formation of the
fully closed conformation. The peptide shows more marked
differences: the glucagon model peptide adopts a helical struc-
ture from Ser8 through toMet27, spanning from the juxtamem-
brane region through to the ECD, in agreementwithmost x-ray
crystal structures on isolated class B ECDs. In contrast, AMhas
a more complex structure, with a non-helical ECD region, in
agreement with the x-ray crystal structure of the isolated ECD
and a helical region that binds to the juxtamembrane region, as
in previous related models and the AM NMR structure (40).
The AM peptide helix binds to the same depth as the glucagon
peptide, as judged by the alignment of the helical region (Fig.
1A), but the glucagon peptide N terminus binds to a greater
depth (consistent with cross-linking data on the related PTH
system (58), whereas AM forms a disulfide-bonded loop con-
sistent not only with the binding of the usual AM(16–52) (26)
but also AM(1–52) (i.e. the N terminus is orientated so that
AM(1–15) can “escape” from the TMbundle). This N-terminal
extension of AM does not seem important for AM activity, and
the AM(15–52) fragment is more consistent with the length of
other peptides in the AM family.
We have pharmacological evidence of RAMP-induced
changes in the function of CLR at the AM1 and AM2 receptors,
which are reflected in conformational differences between our
full-length AM1 and AM2 receptor models. The most striking
difference between the two models is the ECL3 conformation;
interestingly, this is a region that also shows large differences
between the GCGR and CRF1R x-ray crystal structures.
Although only Ala361 in ECL3 shows any kind of differential
activity, the residues flanking ECL3 do show this. Moreover, at
the CGRP receptor, the CLR-RAMP1 complex, Ile360 is
involved in receptor activation as opposed to Ala361 in the AM
receptors (24), giving additional evidence of differential activity
in ECL3. The extracellular region of TM6 in the AM receptors
does contain residues with common-differential activity,
namely Ile352, Pro353, and Trp354. The predicted stacking of
Trp354 with ECL3 in the AM1 receptor combined with changes
in the positions of Ile352 and Pro353 may stabilize the altered
orientation of ECL3. In the AM2 receptor, Trp354 lies perpen-
dicular to its AM1 receptor position, allowing ECL3 to lie fur-
ther toward the center of the peptide binding pocket. Move-
ment of the upper regions of TM3, TM6, and TM7 is involved
in activation of class A GPCRs (59). Some of the differences
observed between the two AM receptors could therefore be
reflected in differential activity of residues in ECL3/TM7
(Ala361 andTyr367) andTM3 (Cys212 and Lys213) in the twoAM
receptors and in the CGRP receptor, where Cys212 is the only
one of these residues involved in receptor activation (24).
TheAMmodel peptide interacts differently with ECL3/TM7
in the two AM receptors (Figs. 1 and 7, A and B) in response to
the effect of the different RAMPs; our models place the RAMP
TM helix between TM6 and TM7 as in the class B secretin
FIGURE 10. Concentration-response curves for the alanine-substituted
AM peptide, F18A AM(15–52). Curves are combined normalized data from
at least three individual experiments S.E. (error bars).
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receptor (60). The greater proximity of the RAMP2 ECD-TM
linker to ECL3 is probably the main factor that contributes to
the reorientation of ECL3 (Fig. 9D). RAMP2 and RAMP3
diverge in sequence in this region, and equivalent RAMP resi-
dues take up different positions relative to AM in the two
models.
The majority of the residues with a common or a common
but differential effect on receptor activation vary little in their
orientation and cluster around the upper TMs of our models
(e.g. the hydrophobic cluster at the top of TM2 (Leu195, Val198,
and Ala199), which is also essential to the function of the CGRP
receptor (24). There are also common and common-differen-
tial residues situated in ECL2 (Asp280, Trp283, and Ile284); due to
the position of the disulfide bond in our AM receptor models,
these lie in close proximity to the upper TMs. Indeed, many
of these common and common-differential residues are also
essential for the activation of the CGRP receptor by both CGRP
and AM (26). ECL2 is particularly important in activation in
class A and B GPCRs (26, 59, 61).
Cys282 in ECL2 forms an essential conserved disulfide bond
with Cys212 in TM3 in both the AM receptors and in the CGRP
receptor (26). However, this bond does not appear to be critical
to activation of the AM2 receptor (or the CGRP receptor). The
smaller pocket in the AM2 receptor causes tighter packing
of the common and common-differential residue network
around the top of the TMs; this more restrained environment
may limit the movement of the side chain of either Cys212 or
Cys282 and allow the AM2 receptor to tolerate an unpaired cys-
teine residue without detrimental perturbation of its structural
integrity and thus activation of the AM2 receptor. Significantly,
ECL3 in the CGRP receptor adopts a similar conformation to
the AM2 receptor (results not shown). In the more open AM1
receptor, this C212A or C282A mutation is fatal to receptor
activation, but precise verification of the mechanism is beyond
the scope of our models. However, we propose that the greater
effect of mutation at the common but differential residues in
the AM1 receptor is related to its degree of openness and hence
stability. Thus, we note that other residues, such as Lys213,
Tyr277, and Tyr278, that are predicted to stabilize ECL2 also
showmore pronounced effects on mutation in the AM1 recep-
tor despite generally adopting similar interactions (Lys213 and
Tyr278) in both structures, presumably because the mutated
AM1 receptor structure is less stable than the mutated AM2
structure.
These changes, especially those in ECL3, serve to alter the
depth, volume, shape, and composition of the model binding
pocket.Whereas the overall position of the docked peptide and
in particular the Phe18 side chain in the peptide binding pocket
FIGURE 11. Smallmolecule druggable sites predicted using PockDrug and viewed fromabove. A, the AM1 site is shown in light blue, and the site residues
that contact AM are shown in blue. B, the AM2 site is shown inmagenta, and the site residues that contact AM are shown in red. This site is narrower and deeper
than the AM1 site; the PockDrug druggability scores for the AM1 and AM2 sites are 0.97 and 0.91, respectively. C andD, surface cutaway views of the receptors;
the different size, conformation, and situation of the pockets are evident from the shading. Selected residues are labeled.
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does not change significantly, the number of close neighbors to
the Phe18 side chain does. These changes have significant impli-
cations for the design of therapeutics that are either specific to
the AM1 or AM2 receptors to treat receptor-specific patho-
physiologies or conversely to harness the common effects of
both receptors. Druggability screening highlighted two differ-
ent druggable pockets for small molecules in the AM1 andAM2
receptors. This indicates scope for specific ligand design by tar-
geting the additional and differential druggable residues of the
two pockets, which lie within the TM domains.
The drug scores of 0.81–0.97 and 0.81–0.91 for theAM1 and
AM2 receptors, respectively, are clearly above the 0.5 threshold,
indicating that they are druggable. Significantly, both sites dis-
play an appropriate balance of hydrophobic and polar residues,
as required for a druggable site (62).Moreover, the difference in
electrostatic potential for these receptors adds to the rationale
for the design of selective AM1 or AM2 ligands. In addition, the
structural model of the AM peptide structure (Fig. 1E) is dis-
tinctly different from that of glucagon and probablymany other
class B peptide ligands and so may also be useful in substrate-
based drug design, especially because there are differences in
the two loop regions. The CRF1R structure shows a narrow
drug-bound channel that sits below the level of our peptide
binding site. Interestingly, both druggability servers indicate
additional druggable sites in this region (20).
We have based our current study on the measurement of
cAMP as the canonical signaling pathway for CLR. It is impor-
tant to note that GPCRs, such as this, also have the capacity to
signal through alternative pathways, and it will be important to
consider these in future studies (55). It is possible that some
residues will have a greater or lesser role, depending on the
pathway measured, indicating further conformational differ-
ences in the receptors.
In summary, we suggest that the change in the predicted
conformation of ECL3 and hence the different TM binding
pockets in the AM1 and AM2 receptors is due to association
with different RAMPs, as described above. The existence of
distinct peptide and small molecule binding pockets with dif-
ferent properties has implications for the design of selective
therapeutics, whether they be smallmolecules or peptides. This
could facilitate the design of ligands to harness the individual
physiological roles of the two AM receptors, validating the
receptors as drug targets.
Our data support the idea that RAMPs act allosterically to
modify the conformation of CLR. This could lead to a range of
possible outcomes, including biasing the receptor toward dif-
ferent ligands or signaling pathways. Two recent reports have
suggested this mechanism for RAMP effects on the related cal-
citonin receptor (63, 64). Allostery between protomers in
receptor oligomers could be a broadmechanism for generating
diversity in GPCR function.
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